Skip to Content
  • Previous Rank
    478
  • Revenues ($M)
    $32,639
  • Revenue Percent Change
    31.1%
  • Profits ($M)
    $18,108
  • Profits Percent Change
    49.6%
  • Assets ($M)
    $51,839
  • Employees
    8,000

The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.

Company Information

CEO
John F. Milligan
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Foster City, CA
Employees8,000
Websitehttp://www.gilead.com
Years on Global 500 List2

Gilead Sciences Rank History

placeholder

Key Financials (last fiscal year)

($ Millions)% change
Revenues ($M)$32,63931.1%
Profits ($M)$18,10849.6%
Assets ($M)$51,839-
Total Stockholder Equity ($M)$18,534-

Profit Ratios

Profit as % of Revenues55.5%
Profits as % of Assets34.9%
Profits as % of Stockholder Equity97.7%